Teleflex (NYSE:TFX) Stock Rating Upgraded by BMO Capital Markets

Teleflex (NYSE:TFX) was upgraded by equities research analysts at BMO Capital Markets to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Several other research firms have also recently issued reports on TFX. Royal Bank Of Canada raised Teleflex from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $135.00 to $155.00 in a research report on Friday, May 8th. Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Wells Fargo & Company boosted their target price on Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Bank of America raised Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price target for the company in a report on Monday, April 13th. Finally, Mizuho set a $140.00 price target on shares of Teleflex in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Teleflex has an average rating of “Hold” and an average price target of $147.44.

Teleflex Price Performance

Teleflex stock opened at $134.16 on Wednesday. The stock has a market cap of $5.94 billion, a P/E ratio of -5.88, a price-to-earnings-growth ratio of 0.97 and a beta of 0.82. The company has a fifty day simple moving average of $129.72 and a 200-day simple moving average of $119.99. Teleflex has a 12-month low of $100.18 and a 12-month high of $139.67. The company has a current ratio of 2.55, a quick ratio of 2.03 and a debt-to-equity ratio of 0.82.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, beating the consensus estimate of $1.21 by $0.18. The firm had revenue of $548.30 million for the quarter, compared to analyst estimates of $536.91 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.Teleflex’s revenue for the quarter was up 32.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Equities analysts expect that Teleflex will post 6.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Teleflex

Institutional investors and hedge funds have recently made changes to their positions in the business. Banque Cantonale Vaudoise boosted its stake in shares of Teleflex by 82.5% during the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after buying an additional 113 shares during the period. V Square Quantitative Management LLC acquired a new position in Teleflex in the 4th quarter valued at about $37,000. UMB Bank n.a. raised its stake in Teleflex by 57.1% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after acquiring an additional 113 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in Teleflex during the 4th quarter valued at approximately $45,000. Finally, Kestra Advisory Services LLC acquired a new stake in Teleflex during the 4th quarter worth approximately $45,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.